
==== Front
Cancer Med
Cancer Med
10.1002/(ISSN)2045-7634
CAM4
Cancer Medicine
2045-7634
John Wiley and Sons Inc. Hoboken

10.1002/cam4.70164
CAM470164
CAM4-2024-05-2586.R1
Review
Review
Human TCR repertoire in cancer
Chen et al.
Chen Lin 1 2
Hu Yuan 2 3
Zheng Bohao 2 4 5
Luo Limei 6
Su Zhenzhen https://orcid.org/0000-0001-5425-5285
6 szz_hx@scu.edu.cn

1 Department of Medical Genetics/Prenatal Diagnostic Center West China Second University Hospital, Sichuan University Chengdu China
2 Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education Chengdu China
3 Department of Anesthesia Nursing West China Second University Hospital, Sichuan University/West China School of Nursing, Sichuan University Chengdu China
4 Department of Obstetrics and Gynecology West China Second University Hospital, Sichuan University Chengdu China
5 Wuxi School of Medicine, Jiangnan University Wuxi China
6 Department of Laboratory Medicine West China Hospital of Sichuan University Chengdu China
* Correspondence
Zhenzhen Su, Department of Laboratory Medicine, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, Sichuan, China.
Email: szz_hx@scu.edu.cn

06 9 2024
9 2024
13 17 10.1002/cam4.v13.17 e7016402 8 2024
06 5 2024
19 8 2024
© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

T cells, the “superstar” of the immune system, play a crucial role in antitumor immunity. T‐cell receptors (TCR) are crucial molecules that enable T cells to identify antigens and start immunological responses. The body has evolved a unique method for rearrangement, resulting in a vast diversity of TCR repertoires. A healthy TCR repertoire is essential for the particular identification of antigens by T cells.

Methods

In this article, we systematically summarized the TCR creation mechanisms and analysis methodologies, particularly focusing on the application of next‐generation sequencing (NGS) technology. We explore the TCR repertoire in health and cancer, and discuss the implications of TCR repertoire analysis in understanding carcinogenesis, cancer progression, and treatment.

Results

The TCR repertoire analysis has enormous potential for monitoring the emergence and progression of malignancies, as well as assessing therapy response and prognosis. The application of NGS has dramatically accelerated our comprehension of TCR diversity and its role in cancer immunity.

Conclusions

To substantiate the significance of TCR repertoires as biomarkers, more thorough and exhaustive research should be conducted. The TCR repertoire analysis, enabled by advanced sequencing technologies, is poised to become a crucial tool in the future of cancer diagnosis, monitoring, and therapy evaluation.

cancer
immunotherapy
next‐generation sequencing
T‐cell receptor
source-schema-version-number2.0
cover-dateSeptember 2024
details-of-publishers-convertorConverter:WILEY_ML3GV2_TO_JATSPMC version:6.4.8 mode:remove_FC converted:06.09.2024
Chen L , Hu Y , Zheng B , Luo L , Su Z . Human TCR repertoire in cancer. Cancer Med. 2024;13 :e70164. doi:10.1002/cam4.70164
==== Body
pmc1 INTRODUCTION

Cancer, an immense threat to human health, has an urgent need for more effective methods of diagnosis, monitoring, and treatment. 1 In recent years, with the successful application of a series of immune checkpoint inhibitors (ICIs) and engineered immune cells in cancer treatment, immunotherapy has become a promising and powerful tool for combating cancer. 2 , 3 However, only a subset of people shows effective immune responses to immunotherapy, suggesting that the efficacy of treatment might be influenced by certain factors, especially immune factors. 4 , 5 Thus, the identification of cancer immunity and immune characteristics is not only helpful for diagnosis, but also to predict and optimize the therapeutic response of tumor eradication. T cells, which mediate cellular immune response and act as essential components in humoral immune response activation, play a critical role in effective antitumor immune response. 6 Concerning T cells, it has been found that T cell receptors (TCRs) are crucial molecular markers that determine the specific recognition abilities of T cells. 7 The collective TCRs of all T cells, known as TCR repertoire, significantly impact almost all health conditions and diseases. 8 TCR repertoire has been found changing dramatically in cancer progression. 9 , 10 , 11 Therefore, the analysis or evaluation of TCR repertoire in cancers will assist in identifying cancer immunity and immune characteristics, promoting the development of diagnostic and monitoring tools, and effective immunotherapies. Here, we first introduced the TCR repertoire and detection methods and reviewed some of the insights that have been made using next‐generation sequencing (NGS) technology to profile TCR repertoires in a healthy population. We then went over the applications of TCR sequencing in the diagnosis, monitoring, and therapies of cancer, and we also discussed several obstacles and potentials of this field.

2 TCR REPERTOIRE

2.1 Generation

On the surface of the T cell membrane, TCR is composed of two disulfide bond‐linked transmembrane proteins: one α chain and one β chain, or one γ chain and one δ chain, which is effectively a heterodimer. 12 , 13 , 14 In the genome, the gene segments of encoding TCR are one of the most complex and broadest loci. 12 , 15 , 16 These loci are found on two chromosomes: β locus is at 7q34, α and δ are at 14q11, and γ is at 7p14. 17 Unlike other known genes, they inherit in a nonfunctional form and then go a special recombination process, a well‐studied process in immunology field, which is termed V(D)J recombination (see Figure 1). TCR is generated in the thymus. Individual gene segment is selected randomly and separately from the large arrays of variable (V), diversity (D), and joining (J) gene segments in the germline genome and then assembled into the variable region via random rearrangement and imprecise recombination, creating a complete receptor. 12 , 18 , 19 , 20 The variable region generated by the somatic recombination can encode three complementarity determining regions (CDRs), known as CDR1‐3. CDR1 and CDR2 are encoded by the V gene, while CDR3 is encoded by the junction region VJ (for α or γ) or VDJ (for β or δ), which varies greatly and is in direct contact with antigens. 12 , 13 , 21 After generation of the TCR, thymocytes (immature T cells) expressing TCRs undergo positive selection, which not only ensures that mature T cells can recognize the antigens presented by self‐MHC, but also completes the lineage commitment of CD4/CD8. 22 , 23 In this process, only thymocytes whose TCRs can moderately bind to self‐MHC molecules receive survival signals and continue to develop, while those that cannot interact with self‐MHC undergo apoptosis. Meanwhile, interaction with MHC class I molecules leads to differentiation into CD8+ T cells, while interaction with MHC class II molecules leads to differentiation into CD4+ T cells. Besides, negative selection can eliminates potentially autoreactive T cells that could cause autoimmune diseases and establish immune tolerance. 23 , 24 Thymocytes that strongly bind to self‐antigens presented by MHC molecules on thymic dendritic cells and medullary epithelial cells receive apoptotic signals and are eliminated. These processes shape the repertoire that mature T cells can recognize foreign antigens presented by self‐MHC molecules while remaining tolerant to self‐antigens to prevent autoimmunity. 25 , 26 , 27 Given the nearly limitless diversity and rare a priori knowledge of foreign antigens, each of us must develop a repertoire of T cells that could recognize any aberrant protein during life. Fundamentally, this capacity depends on the TCR structural diversity that is the result of V(D)J recombination. In the process of V(D)J recombination, in addition to the diversity of join, each join follows a random insertion or deletion at the junctions, producing an inherent imprecision of join and a more diverse repertoire. 28 , 29 Because of the low probability of producing a same V(D)J recombination twice in an individual, the TCR sequence can be used as a unique identifier of T cell clones. 30 Each clonotype represents a unique TCR variant that can be traced back to a specific T cell clone. 31 Thus, the study of TCR repertoire is a useful proxy for measuring antigen‐driven clonal expansion of T cells and longitudinal clonal dynamics and heterogeneity of the T cell response. In this review, we refer to TCR repertoire as the collection of TCRs within a given T cell population. Theoretical estimates of TCR types cover a wide range (1011 to >10 18 ), depending on the assumptions including the length of the nontemplated base sequences inserted at the segment junction and distribution made in diversity calculations. 16 , 31 , 32 The great diversity of TCR represents the biggest challenge in TCR research as there are still technical limitations in obtaining unbiased absolute count data of TCR types.

FIGURE 1 αβT cell development. Lymphoid precursors derived from bone marrow travel to the thymus. These double‐negative (DN) early T cells express neither CD4 nor CD8 and can be subdivided into four stages of differentiation. During lymphocyte development, specificity and diversity result from the V(D)J recombination of distinct variable (V), diversity (D), and joining (J) gene segments. At the DN3 stage, T cell development begins with the joining of D and J gene segments for the TCRβ chain. The V gene segment is joined at the DN4 stage. Each join in the process is preceded by a random insertion or deletion of nucleotides at the junctions. Cells that express a pre TCR consisting of a functional TCRβ chain and an invariant pre TCRα chain proceed to the subsequent stage of development, whereas cells lacking pre TCR undergo apoptosis. The remaining cells undergo ligand‐independent and ligand‐dependent expansion, and TCRα rearrangement including VJ recombination, resulting in expression of TCRs and double positive of CD4 and CD8 (DP). The cells without TCR expression, with TCR that does not recognize self‐major histocompatibility complex (self‐MHC) molecules and with TCR that has excessive affinity for self‐peptide–MHC complex would die (positive selection and negative selection). The remaining cells with TCRαβ and single positive (SP) become naive αβT cells.

2.2 Detection methods

Some techniques have been used for the analysis of TCR repertoire. Spectratyping, an approach consisting of a CDR3 fragment analysis through capillary electrophoresis, has been applied to screen the TCR repertoire by analyzing peak area and shape of CDR3 profiles. 33 , 34 This method can show the degree of TCR skewing (an imbalance in the diversity of the TCR repertoire) and oligoclonality (the presence of a limited number of TCR clones within a population), but not present specific TCR information. 35 Spectratyping can reveal TCR skewing by showing peaks that represent the overrepresentation of certain TCR clones, leading to an abnormal distribution profile, and demonstrate oligoclonality by showing a restricted set of peaks, each representing a dominant TCR clone, resulting in a narrow and peaked CDR3 distribution profile. Flow cytometry can achieve the information of TCR at protein level by specific anti‐TCR antibodies. 36 However, the availability of specific antibodies restricts comprehensive analysis of the TCR repertoire. Sanger sequencing can achieve the information of TCR in DNA level up to several 100 cells. 37 Nonetheless, low‐throughput analysis limits a broader understanding of the TCR repertoire. Over the past decade, the emergence and advancement of NGS technology have provided a robust platform for comprehensive analysis of the TCR repertoire. 38 NGS is an advanced sequencing technology that allows for the rapid sequencing of large amounts of DNA or RNA. Although the detection process mainly includes sample preparation, PCR amplification, sequencing, and data analysis, DNA sequencing and RNA sequencing differ in terms of the information obtained, their respective applications, complexity, data interpretation, and temporal resolution. 31 , 39 , 40 , 41 , 42 , 43 , 44 DNA sequencing of TCRs provides information about the potential TCR gene segments present in the genome (germline configuration), which reveals the genetic predisposition for TCR diversity, provides a snapshot of the potential TCR repertoire that an individual or population can generate but does not directly indicate which TCRs are actively being used by T cells. The data interpretation of DNA sequencing of TCRs mainly involves identifying germline gene segments and potential rearrangements, and it is commonly used to study the genetic predisposition and potential diversity of TCRs in an individual or population. RNA sequencing of TCRs focuses on the mRNA transcripts encoding the TCRs, which reflects the TCR sequences that are transcribed and translated into proteins by T cells, providing insights into the actively utilized TCR repertoire and the diversity of T cells responding to specific antigens or conditions. RNA sequencing is usually used to analyze the functional TCR repertoire under specific conditions such as disease states, immune responses, or following treatments like immunotherapy. The data interpretation of RNA sequencing of TCRs is complex due to the variability introduced by post‐transcriptional modifications, alternative splicing, and the need to distinguish between truly expressed TCR sequences and sequencing artifacts. In summary, DNA sequencing of TCRs provides information about the potential diversity encoded in the genome, while RNA sequencing reveals the active repertoire of TCRs being expressed by T cells. Both approaches are valuable for different aspects of understanding immune responses and T cell biology. With the generation of massive sequencing data, new approaches of computational data analysis, as well as data sharing, archiving, and aggregation also developed, making quantitative analysis, diversity delineating, and dynamic evolution tracking of the astronomical TCR repertoire possible. 45

2.3 Characterized metrics

The data set generated by TCR sequencing based on NGS technology usually contains millions of sequences. Several indices have been developed to characterize the TCR repertoire (Table 1). The metrics to characterize TCR repertoire mainly include diversity and clonality. The former reflects the richness of TCR types, while the latter mainly reflects the evenness of TCR distribution. 46 The changes in TCR repertoire reflect the immune process, and the analysis of these processes will help to understand the antigen‐specific T cell response. 35 For example, the specific T cell clonal expansion induced by antigen will lead to the change of TCR clonal distribution and the increase of clonality, while the depletion or migration of T cells may lead to the decrease or increase of TCR diversity in the microenvironment where immune response occurs (such as intratumor). 31 In the published studies, the most commonly used indicators to characterize the diversity of repertoire are based on the Shannon's and Simpson's diversity indices. 47 The characteristic index realizes the statistical comparisons of TCR repertoire within individuals (such as different time periods) and among individuals, and thus provides a possible hierarchical index for developing a biomarker of the disease monitoring and treatment response, which still needs to be further verified.

TABLE 1 Metrics for description and evaluation of TCR repertoire.

index	Calculation formula	Significance	
Shannon entropy 48	−∑i=1npilogepi

n, number of clone types;

pi, the proportion of the i‐th clone relative to the total n clones.

	Shannon entropy can evaluate the diversity, reflect the CDR variability and account for both richness and relative abundance. The higher the index, the higher the diversity, the more diverse distribution.	
Renyi entropy 49	11−αlog∑Piα

α, variable.

	Renyi entropy can evaluate the diversity according to the extent of clonal expansion and distribution. It depends on the variable α. α > 1 means more weight on the abundant species (such as highly expanded TCRs), while α < 1 means more weight on the rare ones. It provides more extensive information than a single index because of the considering of differently weighted abundances.	
Simpson index 50	∑Pi2

pi, the proportion of each productive rearrangement.

	Simpson index can evaluate the diversity. High simpson index indicates an uneven distribution of one or a few clones and a less diverse repertoire.	
Morisita‐Horn index 51	2p1p2p12+p22

p, the proportion of each clone.

	Morisita‐Horn index can evaluate the similarities of repertoires. It is often more suitable to be used in high abundance components, because of the insensitivity to the low abundance components (such as rare TCRs).	
Clonality index 52	1−−∑i=1npilogepilogen

n, number of clone types;

pi, the proportion of the i‐th clone relative to the total n clones.

	Clonality index may evaluate clone expansion, indicate the frequency of clone expansion, and measure the difference between two TCR repertoires with varying numbers of clones. It is based on the normalized Shannon entropy, always between 0 and 1. The larger the value, the more clone expansion. The value 1 means monoclonal distribution.	
Pielou's evenness index 53	−∑i=1npilogepilogs

n, number of clone types;

pi, the proportion of the i‐th clone relative to the total n clones;

s, the number of unique sequences.

	Pielou's evenness index permits comparisons between samples with varying total read counts. On a scale from 0 to 1, the higher the score, the more uniform the distribution. The low score indicates clone skewing due to the biased expansion.	
High expanded clone (HEC) 54	∑i=1npi

n, number of clone types;

pi, the proportion of the i‐th clone relative to the total n clones.

	HEC is used to describe the stare of TCR library. It is calculated as the sum of all sequences whose abundance is greater than the threshold. The common threshold is 0.01% or 0.1%, which can be adjusted according to research needs.	

3 TCR REPERTOIRE IN HEALTH

In humans, blood is the major accessible sample, although it contains only 2%–3% of the total T cells. 55 There are an estimated 5–10 × 109 T cells in the blood, containing about 1–10 × 106 unique TCR β‐chains, with a similar diversity for TCR α‐chains. 31 , 56 , 57 , 58 , 59 , 60 γδ T cells are detected at frequencies of 1%–5% of T cells in peripheral blood, but the specific diversity of TCR γ or δ chains is not well understood. 61

The diversity of the TCR repertoire, mainly established during the fetal period and early childhood, is not static throughout life. 62 Although there is no longitudinal data from cord blood to adulthood, systematic comparisons of TCR repertoires among individuals of different ages indicate that TCR diversity decreases with age. Age‐related contractions in the TCR repertoire are approximately 2–4 fold in healthy elderly subjects compared to young adults. 63 , 64 , 65 It is estimated that 5 × 104 clonotypes of TCR β are lost each year, ranging from 5 × 106 clonotypes in the youngest (6–25 years) to 2.6 × 106 clonotypes in long‐lived donors (71–90 years). 56 This reduction may be related to age‐related thymic atrophy or involution, which could reduce the output of new naive T cells. 66 , 67

Meanwhile, the TCR repertoire is also shaped by an accumulation of “immunization diary” throughout life. In reality, TCR gene recombination in developing thymocytes results in each new naive T cell expressing a unique TCR, and naive T cells predominate in peripheral blood at birth with sizable diversity. 68 , 69 When the TCR of a naive T cell binds to a structurally compatible peptide major histocompatibility complex (pMHC) on an antigen‐presenting cell, clones rapidly proliferate and differentiate with the help of costimulatory molecules, generating a population of activated/effector T cells carrying identical TCRs. Normally, after the antigen that triggered the immune response has been cleared, the expanded pool gradually shrinks and persists as a smaller number of memory cells ready for another potential encounter with the antigen. With the gradual accumulation of memory T cells, the TCR repertoire is constantly shaped by immunological challenges and TCR input. 70 As a result, the overall diversity of the TCR repertoire reduces, which is one of the molecular hallmarks of T cell aging, as also seen in the cancer microenvironment. 71 , 72

Another important topic of TCR repertoire studies is public TCRs, which are shared among T cells of multiple individuals. Although the default expectation has been that the TCR repertoire in each individual would be largely unique or private due to high diversity, a large and growing body of research has shown that different individuals often use similar or identical TCRs, at least for one chain of the heterodimer. Previous studies have supported the existence of such public TCRs by showing a similar amount of shared CDR3 clonotypes between monozygotic twins and unrelated babies, and the presence of natural killer T (NKT) and mucosa‐associated invariant T (MAIT) cells with identical TCRα chain sequences in all humans. 73 , 74 , 75 Recently, the overlap has been reported to be 8% for TCRβ chains and 11% for TCRα chains in peripheral blood of three individuals. 76 The overlap in the thymus is 6.1% and 46.7% for TCRβ and TCRα chains, respectively. 77 Some studies also focus on the clonal overlap in T cells of different types and locations. For example, a study comparing autoreactive conventional T cells (Tconv) with thymically derived forkhead box protein 3 (FoxP3) + regulatory T cells (tTregs) in human adult and cord blood found virtually no clonotype overlap of TCRβ CDR3. 78 Another study found an overlap of TCRβ in 5% of naive CD4+ and 3.5% of naive CD8+ T cells, and 2.3% of memory CD4+ and 0.4% of memory CD8+ T cells, respectively. 76 Comparisons of naive and memory clonotypes in human spleen and lymph nodes found minimal overlap between tissues. 79 When the total TCR repertoire was evaluated between individuals using standard clinical blood samples, it was observed that less than 0.2% of the repertoires were convergent between individuals. 80

Currently, several factors are considered to affect clonotype sharing, including convergent recombination (numerous V(D)J recombination events converging to generate the same nucleotide sequence), recombinatorial biases (different gene segments having preferences in usage frequency and pairing), and precursor frequency (different naive T cell precursors being made across a wide range of frequencies). 35 , 81 , 82 In addition, with the discovery of public TCRs enriched in antigen‐experienced populations, antigen‐driven selection is considered to be an important factor in increasing the frequency of these similar clonotypes. 83 , 84 , 85 Although the discovery of antigen‐related public TCRs does not imply that public TCRs are potent or protective species, a growing number of such public TCRs have been found in various immune responses, such as infectious diseases, autoimmunity, and malignancy, suggesting possible virus‐neutralizing activity or other useful functional properties. 86 , 87 , 88 As more and more individuals' repertoires are sequenced in response to specific antigenic exposures, public TCRs will continue to be found. It would be very appealing if the frequency of a particular TCR could predict whether an individual will have a good response to a specific antigen. If this becomes practical in the future, it could be helpful for vaccine development and other planned manipulations of the immune system, such as engineered immune cells for therapeutic intervention in cancer.

4 TCR REPERTOIRE IN CANCER

TCR repertoire analysis is invaluable for quantitatively evaluating immune diversity, assisting with early‐stage cancer diagnosis, treatment selection, and prognosis prediction. Profiling TCR repertoires using NGS technologies and associated bioinformatics pipelines has resulted in a powerful tool that can characterize the breadth, strength, and dynamics of the antitumor immune response.

4.1 TCR repertoire in solid tumor

In theory, a high diversity of the TCR repertoire increases the possibility of tumor‐specific T cells recognizing corresponding antigens and inhibiting cancer cell growth, thereby limiting immune escape. In reality, significantly decreased TCR repertoire diversity has been observed in peripheral blood of patients with most solid malignancies such as glioblastoma, colorectal cancer, lung cancer, and melanoma. 89 , 90 The relationship between decreased TCR diversity and tumorigenesis is unclear. It may be that decreased diversity leads to declined antitumor ability, tumorigenesis consumes specific TCR species, or both. Some studies, such as those finding greater TCR repertoire diversity in the peripheral blood of prostate cancer patients compared to healthy donors, add complexity to this issue. 91 Based on the characteristics, TCR repertoire analysis could be used to distinguish cancer patients from healthy adults and from patients with other diseases. 92 , 93 Further studies have confirmed that the TCR repertoire could serve as a biomarker to monitor cancer immune response. 94 , 95 , 96 In the future, TCR repertoire analysis might become a powerful tool for noninvasive tumor detection and provide insights for tumor detection and monitoring.

Moreover, the TCR repertoire shows a dynamic trend in cancer progression. One study showed that the peripheral TCR diversity decreased while shared clones increased successively in healthy people, patients with cervical intraepithelial neoplasia, early cervical cancer and advanced cervical cancer, indicating that peripheral TCR diversity decreased with cervical cancer progression and that there may be disease‐specific antigen‐mediated immune responses. 97 Similarly, metastasis‐positive lymph nodes showed a significantly lower TCR diversity and more shared clonotypes compared to metastasis‐negative lymph nodes in colorectal cancer. 98 In lung cancer, in addition to age‐related decline, peripheral TCR diversity further reduced in patients with larger tumors or more metastatic sites, and the relapsed group exhibited lower diversity than the untreated group. 90 Dynamic TCR repertoire analysis may serve as a useful indicator of cancer development and guide immunotherapy.

The TCR repertoire is also associated with cancer prognosis. Depending on the cancer type, both high and low diversity in tumor tissue or blood TCR repertoire can be associated with better prognosis. For instance, in melanoma, patients with late relapse and long progression‐free survival (PFS) showed significantly higher TCR repertoire diversity in blood than those with rapid progression and poor prognosis. 99 In gastric cancer, low diversity of TCR repertoire within the tumor‐adjacent mucosal tissue is associated with a poor clinical prognosis in patients, and the mucosal TCR repertoire diversity index is an independent predictor for survival of patients. 100 In lung cancer, the higher TCR repertoire diversity in tumor tissues is associated with worse cancer outcomes, while patients with higher TCR diversity in peripheral blood shows a longer PFS. 90 , 101 In cervical cancer, less clonotypes in the TCR repertoire of sentinel lymph node was associated with the poor prognosis. 97 In mycosis fungoides, the high TCR clonality in tumors is related to the decrease of PFS and overall survival. 102 The relationship between TCR diversity and cancer is summarized in Table S1. These findings highlight the need for more precise studies on specific tumor types.

Analysis of public TCR clones amplified in primary and metastatic tumors can enhance understanding of antigen‐specific TCRs and predict prognosis. 103 Notably, considering the ease and noninvasiveness of peripheral blood sampling, most studies are based on peripheral blood samples, which may not accurately reflect the tumor microenvironment. Some studies have extended the analyses beyond peripheral blood, showing significant differences between intratumoral and peripheral blood TCR repertoires. 101 , 104 , 105 , 106 , 107 More evidence suggests TCR repertoire heterogeneity, differing in various cancers and within different regions of the same tumor. 103 , 108 , 109 On the one hand, it is due to the differences in immune microenvironment in different cancer types. A group of expanded T cell clones which may spatially confine to the tumor microenvironment mainly reacting to tumor antigens. On the other hand, it may be related to tumor neoantigens. This view is supported by number of studies that reported TCR heterogeneity landscape in both primary and metastatic tumors. 109 , 110 , 111 , 112 TCRs present in tumors or other regions may mainly represent the response to tumor antigens found in cancer cells. Because neoantigens can gradually appear in the process of tumor evolution, the number of neoantigens in different regions of the tumor may vary greatly, which contributes to the spatial heterogeneity in TCR repertoire. In turn, TCR heterogeneity can reflect specific selective amplification of TCR in tumors and is related to the number of somatic mutations leading to tumor heterogeneity. 113 , 114 In lung adenocarcinoma, higher TCR intratumor heterogeneity is associated with higher predicted neoantigen heterogeneity, higher risk of postsurgical relapse, and shorter disease‐free survival, suggesting potential clinical significance of TCR repertoire heterogeneity. 112

4.2 TCR repertoire in nonsolid tumor

Patients with hematological (but non‐T cell) cancers, such as acute myeloid leukemia (AML), showed significantly higher clonality and lower diversity of blood TCR repertoire, even after excluding the age effects. 89 , 115 In diffuse large B‐cell lymphoma (DLBCL), the TCR diversity within DLBCL nodes is abnormally narrow relative to nonpathological node tissues. 116 This change is expected due to the infiltration of primary and/or secondary lymphoid organs in these patients, which potentially hinder the emigration of hematopoietic precursors to the thymus and/or peripheral T cell expansion. In T lymphoid malignancy, TCR shows highly clonal expansion and significantly decreased diversity. 117 As TCR repertoire could reflect the immunological status and abnormality, TCR repertoire analysis based on NGS can be used to detect malignant clones, identify clonal amplification and track minimal residual disease (MRD) in some blood disorders, demonstrating better sensitivity and accuracy than conventional methods. 39 , 93 , 118 , 119 Moreover, more obvious clonal amplification is observed in patients with AML recurrence than in the first diagnosis. 120 Similarly, high TCR clonality in DLBCL associates with poor outcome in conventional frontline therapy. 116 These suggest that TCR repertoire analysis may be related to the progression and prognosis, which needs further exploration.

5 TCR REPERTOIRE DURING CANCER TREATMENT

Cancer poses a significant threat to human health, and its treatment has always been a major focus. Traditional anticancer therapies such as surgical intervention, chemotherapy, and radiotherapy mainly focus on removing or killing tumor cells directly. With the success of immunotherapy, represented by immune checkpoint inhibitors (ICIs) in improving cancer patient survival, recent researches on cancer treatment pay a large of attention to the anticancer effect of the immune system. 121 As crucial factors of the anticancer immune response, T cells affect and participate in the process of immunotherapy and traditional treatments. 122 , 123 In addition, detecting tumor‐specific or neoantigen‐specific TCRs is a key step that directly affects treatment efficacy. 124 Thus, in‐depth analysis of the TCR repertoire has a potential to provide necessary insights for understanding individual tumor and immunity and guide treatment.

5.1 TCR repertoire in traditional treatments

For most solid tumors, timely surgical intervention is the first tier treatment. In patients with colorectal cancer, peripheral TCR expansion clone were higher than those in healthy controls, but decreased after surgery. 54 In resectable non‐small cell lung cancer, an association was observed between higher intratumoral TCR clonality and reduced percent residual tumor at the time of surgery. 125 The change of TCR repertoire after surgery, on the one hand, is due to the removal of tumor; on the other hand, it may also be related to the effect of surgical stress on immune state. 126 Although the reasons for these changes are complex, TCR repertoire can characterize the overall immune state to some extent and has potential for predicting surgery prognosis.

Radiotherapy and chemotherapy are not only the main treatment of nonsolid tumors, but also often combined with surgery to treat solid tumors. Experimental models indicate radiation therapy increases TCR diversity, which contributes to response. 122 TCR repertoire analysis in two cohorts (glioblastoma and chronic lymphocytic leukemia) with paired pre‐ and post‐treatment blood samples showed that there was no drastic change in diversity or clonality after chemotherapy, but there was almost no clonal overlap, that is, TCR remodeling after chemotherapy changes the clone type. 89 Surprisingly, even in elderly cancer patients, age‐specific metrics of repertoire can be completely restored after T cell lymphotoxic chemotherapy. It suggests that it may be unnecessary to worry about the drastic and uncompensated loss of diversity in the elderly population caused by chemotherapy, which opens up an interesting new perspective on immunosenescence and immune reconstruction in cancer patients, and may affect the way we think about immunologic and cytotoxic cancer treatment. In addition, a severe restricted diversity or highly clonality of peripheral blood TCR repertoire at baseline was reported to associate with poor outcome treated with chemotherapy. 116 , 127 , 128 Thus, significantly reduced age‐adjusted TCR diversity in cancer patients may indicate TCR repertoire defects, which could be both a consequence and a potential basis for carcinogenesis.

5.2 TCR repertoire in immunotherapy

Immunotherapeutic strategies activate the immune system and boost tumor‐specific immune responses. The most effective cancer immunotherapies currently include ICIs, tumor‐specific antigen‐based cancer vaccines, adoptive cell transfer (ACT), and antibody‐dependent cellular cytotoxicity (ADCC). 129 , 130 , 131 , 132 , 133 , 134 However, not all patients show clinical improvement from immunotherapy, and adverse events can occur. 135 , 136 At present, there are few biomarkers that can be used to predict clinical benefit and monitor post‐treatment immune response. Although the relationship between TCR repertoire and ACT or ADCC therapy response is unclear, studies have shown that TCR repertoire analysis has great potential in ICIs and cancer vaccine immunotherapies.

5.2.1 ICIs

As one of the representatives of immunotherapy, ICIs have become a powerful clinical strategy for combating cancer. The blockade of two vital molecules for T cell related immune response, cytotoxic T lymphocyte‐associated antigen 4 (CTLA‐4) and programmed cell death protein 1 (PD‐1), have been approved for clinical application. Despite a subset of cancer patients has obtained unprecedented clinical benefits from this treatment, the majority of patients across different cancers does not benefit from this costly therapy. It is not clear how ICIs induce persistent tumor response or autoimmune toxicity. The clinical need for biomarkers that predict the likelihood of patients benefiting from these drugs before or early treatment has also not been met. The TCR repertoire analysis in the process of immune checkpoint blockade may provide insights into the mechanisms, and further predict clinical benefits and outcomes.

Anti‐CTLA‐4

Universal increased peripheral blood TCR diversity after anti‐CTLA‐4 therapy is reported. 53 , 137 , 138 , 139 This may be attributed to the fact that CTLA‐4 is a checkpoint involved in the early initiation stage of immune response. However, the relationship between TCR repertoire and clinical response is controversial. Some studies showed that the peripheral diversification is irrespective of clinical responses for anti‐CTLA‐4 treatment, 53 , 140 while other studies suggested TCR repertoire features of patients could potentially be used as a predictive biomarker for clinical response. 137 , 139 , 141 , 142 , 143 , 144 The differences of CTLA‐4 blocking antibodies (such as tremelimumab and ipilimumab), sample type and detection technology may be the reasons for the different results about the relationship between TCR repertoire and clinical responses. Significantly, the TCR repertoire is highly different before and after anti‐CTLA‐4 treatment, and the overlap is low. 53 , 139 This suggests that anti‐CTLA‐4 therapy can promote a rapid influx of new T cell clones and broaden the circulating TCR repertoire. However, this broadening is nonspecific because the increased diversity of peripheral TCR has an association with anti‐CTLA‐4 toxicity, which in part reflect checkpoint inhibition may also result in mobilization of auto‐reactive T cells. 53 , 138

Anti‐PD‐1

Increased peripheral TCR diversity was also found in tumor patients after anti‐PD‐1 treatment. 141 However, more studies have shown that anti‐PD‐1 treatment is mainly related to TCR clonal expansion rather than diversification, suggesting that anti‐PD‐1 may be more conducive to the maintenance and expansion of existing antitumor T cells. 145 , 146 , 147 , 148 , 149 Considering the inverse association between TCR clonality and percent residual tumor at the time of surgery, it provides a justification for the use of anti‐PD‐1 before surgery. 125 Unlike anti‐CTLA‐4, the clonality of TCR repertoire shows a close relationship with the clinical response of anti‐PD‐1 treatment. A high clonality in pretreatment relates to a longer progression‐free survival and better response to anti‐PD‐1 therapy. 145 , 146 , 150 Meanwhile, following PD‐1 blockade therapy, the clonality increase has been found to associate with clinical response in different cancers, such as melanoma, non‐small cell lung cancer, pancreatic cancer, and merkel cell carcinoma. 139 , 147 , 151 , 152 Thus, it may be feasible to assess the response of checkpoint blockade before or early treatment by monitoring the TCR repertoire.

5.2.2 Cancer vaccines

Therapeutic cancer vaccines usually include selected tumor antigens, immune activating adjuvants, and even immune cells such as dendritic cells (DCs). 153 Their goal is to induce tumor regression, eradicate MRD, establish lasting antitumor memory, and avoid nonspecific or adverse reactions. However, tumor‐induced immunosuppression and immune resistance pose a major challenge to achieve this goal. TCR repertoire analysis could provide a better understanding of the breadth, intensity, and dynamics of antitumor immune response, which will help to improve vaccine design.

Sipuleucel‐T, an FDA approved DC‐focused vaccine, has been reported to promote the recruitment of T cells into prostate tissue and increase the diversity of TCR in the tumor tissue, so as to enhance antitumor immunity. 91 Similarly, other vaccines change the clonality or/and diversity of TCR repertoire, as well as the neoantigen‐specific immunity in cancers, including glioma, melanoma, lung cancer, and mesothelioma. 154 , 155 , 156 , 157 Moreover, the clinical response to cancer vaccine is closely related to the characteristics of TCR repertoire before and after treatment. 156 , 157 Patients with high clonality of TCR repertoire before immunotherapy and increased diversity after vaccine treatment show a better clinical response, which is similar with anti‐CTLA4 or anti‐PD1 treatment in other cancers. 137 , 147 It seems that the presence of circulating expanded TCR clones is generally beneficial for the clinical response to immunotherapy. However, it is not clear whether these clones reflect a pre‐existing tumor‐specific TCR. It is worth noting that although the change trend of TCR repertoire after using anti‐CTLA‐4 or anti‐PD‐1 is similar to that after vaccine treatment, clinical researches on mesothelioma using anti‐CTLA‐4 or anti‐PD‐1 were unsuccessful or little effective, 158 , 159 , 160 suggesting that different immunotherapy approachws may target a certain type of T cell subsets, and the change of single subset will affect the TCR repertoire analysis. Therefore, further identification of TCR clonetypes associated with immunotherapy will contribute to predict treatment‐related clinical outcomes.

The success of cancer immunotherapy depends on the inducing and producing effective tumor specific immune response. The combination of different immunotherapy methods (such as cancer vaccine and ICIs) may synergistically enhance antitumor response and optimize the potential of immunotherapy. 161 In order to further improve the effect of immunotherapy, a deeper understanding of host‐tumor interaction and tumor immune escape strategy is required. The existing researches show that the diversity and clonality of TCR repertoire are closely related to the clinical responses to immunotherapy, providing insights into the mechanisms. As immunotherapy act on the immune components rather than tumor cells directly, it is likely that the same features of the TCR repertoire could be generalized to predict response to immunotherapy for most patients eligible for this treatment. A broader research scope, larger sample sizes, and prospective validation are expected to determine whether TCR repertoire analysis can be used as a biomarker for stratification and monitoring of immunotherapy, so as to prognosticate the clinical benefits.

6 FUTURE DIRECTIONS

Overall, TCR repertoire appears to be a biomarker of antitumor adaptive immunity and might also be predictive markers of responses to cancer immunotherapy. Although TCR repertoire analysis of tumor microenvironment may better reflect antitumor immunity, blood samples will be the preferred samples for analysis because they are easy to obtain and noninvasive. Therefore, it is necessary to explore the TCR repertoire consistencies and differences between peripheral blood, tumoral, and adjacent normal tissues. The dynamic characteristics of TCR repertoire in different cancers also deserve further discussion. In addition to monitoring, we expect that TCR repertoire analysis can also determine whether clonally expanded T cells actually recognize tumor specific antigens in individual patients, and then be used to create tumor reactive T cells.

Due to CDR3 of TCRβ Chain represents the most diversity of TCR repertoire, most studies have focused on it. Although sequence of TCRβ can be used as a unique identifier for a specific T cell, it cannot be used alone to determine the antigen specificity or tumor reactivity of a specific T cell. It may be helpful to predict the peptide specificity of TCR by adjusting the method to obtain the information of both chains of TCR. At the same time, the γδTCR deserves more research.

Moreover, the analysis of TCR repertoire should be more combined with the phenotypic status of T cells. The current studies mainly focuses on the analysis of molecular characteristics, without combining the staining and sorting information of T cell markers to obtain more detailed information about T cell clonotypes. The changes of different T cell subtypes may lead to the same TCR repertoire changes, but their actual immune effects are different. For example, clonal expansion of regulatory T cells is certainly more detrimental for patients than that of cytotoxic T cells. Therefore, the combination of TCR sequencing and T cell phenotypic characteristics will be more conducive to explore the antitumor immunity.

It should be further noted the opening up of novel approaches to study TCR repertoire. The index of diversity or clonality mainly reflects the distribution of repertoire (such as richness and evenness). The analysis methods or indicators focusing on TCR functions are worthy of efforts. For example, based on the assumption that TCRs that reacted to the same antigen have similar CDR3 amino acid sequences, recent studies have developed cluster analysis of highly similar sequences, providing biomarkers for tumor monitoring and treatment response that are more powerful than other indexes. 162 , 163 , 164 Some new computing methods, especially machine learning algorithms, also provide new possibilities for predicting TCR antigen specificity. 165 The new methods that will properly solve the current challenges in TCR repertoire analysis of cancers are highly anticipated.

7 CONCLUSION

TCR repertoire analysis is increasingly becoming an indispensable weapon in cancer immune research. With the further decline of sequencing cost, the more standardized protocols, and the more reliable and user‐friendly computational tools, TCR repertoire analysis will be more and more used in clinical context, including monitoring the occurrence and progression of diseases, evaluating the response to treatment, patient stratification, prognosis evaluation and so on. In addition, with the development and application of computational methods and artificial intelligence, the most powerful impact of TCR repertoire analysis may be to annotate the antigen‐specific repertoire in antitumor immune response, identifying tumor neoantigens and T cells that respond to tumor antigens. By then, cancer immunotherapy such as adoptive cellular therapy and cancer vaccine will enter a new era.

AUTHOR CONTRIBUTIONS

Lin Chen: Formal analysis (lead); writing – original draft (lead). Yuan Hu: Writing – original draft (supporting). Bohao Zheng: Formal analysis (supporting); writing – original draft (supporting). Limei Luo: Formal analysis (supporting). Zhenzhen Su: Conceptualization (lead).

CONFLICT OF INTEREST STATEMENT

The authors declare that they have no conflict of interest.

Supporting information

Table S1.

DATA AVAILABILITY STATEMENT

Not applicable.
==== Refs
REFERENCES

1 Sung H , Ferlay J , Siegel RL , et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71 (3 ):209‐249.33538338
2 Topalian SL , Wolchok JD , Chan TA , et al. Immunotherapy: the path to win the war on cancer? Cell. 2015;161 (2 ):185‐186.26042237
3 Liu XS , Mardis ER . Applications of Immunogenomics to cancer. Cell. 2017;168 (4 ):600‐612.28187283
4 Havel JJ , Chowell D , Chan TA . The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19 (3 ):133‐150.30755690
5 Chen DS , Mellman I . Elements of cancer immunity and the cancer‐immune set point. Nature. 2017;541 (7637 ):321‐330.28102259
6 Xu MM , Pu Y , Zhang Y , Fu YX . The role of adaptive immunity in the efficacy of targeted cancer therapies. Trends Immunol. 2016;37 (2 ):141‐153.26778079
7 Zinkernagel RM , Doherty PC . Restriction of in vitro T cell‐mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature. 1974;248 (5450 ):701‐702.4133807
8 Woodsworth DJ , Castellarin M , Holt RA . Sequence analysis of T‐cell repertoires in health and disease. Genome Med. 2013;5 (10 ):98.24172704
9 Guo L , Bi X , Li Y , et al. Characteristics, dynamic changes, and prognostic significance of TCR repertoire profiling in patients with renal cell carcinoma. J Pathol. 2020;251 (1 ):26‐37.32073142
10 Wang H , Yuan Y , Lu C , et al. Analysis of T‐cell receptor repertoire in peripheral blood of patients with pancreatic cancer and other pancreatic diseases. J Cell Mol Med. 2021;25 (8 ):3991‐4000.33682267
11 Zhang Y , Mudgal P , Wang L , et al. T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex‐96 vaccine trial against newly diagnosed glioblastoma. Onco Targets Ther. 2020;9 (1 ):1749476.
12 Hedrick SM , Cohen DI , Nielsen EA , Davis MM . Isolation of cDNA clones encoding T cell‐specific membrane‐associated proteins. Nature. 1984;308 (5955 ):149‐153.6199676
13 Chien YH , Iwashima M , Kaplan KB , Elliott JF , Davis MM . A new T‐cell receptor gene located within the alpha locus and expressed early in T‐cell differentiation. Nature. 1987;327 (6124 ):677‐682.2439914
14 Gross G , Waks T , Eshhar Z . Expression of immunoglobulin‐T‐cell receptor chimeric molecules as functional receptors with antibody‐type specificity. Proc Natl Acad Sci USA. 1989;86 (24 ):10024‐10028.2513569
15 Yu NL , Alt FW , Reyes J , Gleason M , Zarrin AA , Jung D . Differential utilization of T cell receptor TCR alpha/TCR delta locus variable region gene segments is mediated by accessibility. Proc Natl Acad Sci USA. 2009;106 (41 ):17487‐17492.19805067
16 Davis MM , Bjorkman PJ . T‐cell antigen receptor genes and T‐cell recognition. Nature. 1988;334 (6181 ):395‐402.3043226
17 Lefranc MP , Giudicelli V , Duroux P , et al. IMGT®, the international ImMunoGeneTics information system® 25 years on. Nucleic Acids Res. 2015;43 (Database issue ):D413‐D422.25378316
18 Saito H , Kranz DM , Takagaki Y , Hayday AC , Eisen HN , Tonegawa S . A third rearranged and expressed gene in a clone of cytotoxic T lymphocytes. Nature. 1984;312 (5989 ):36‐40.6208487
19 Cobb RM , Oestreich KJ , Osipovich OA , Oltz EM . Accessibility control of V(D)J recombination. Adv Immunol. 2006;91 :45‐109.16938538
20 Schatz DG , Swanson PC . V(D)J recombination: mechanisms of initiation. Annu Rev Genet. 2011;45 :167‐202.21854230
21 Davis MM , Jay Boniface J , Reich Z , et al. Ligand recognition by alpha beta T cell receptors. Annu Rev Immunol. 1998;16 :523‐544.9597140
22 Singer A , Adoro S , Park JH . Lineage fate and intense debate: myths, models and mechanisms of CD4‐ versus CD8‐lineage choice. Nat Rev Immunol. 2008;8 (10 ):788‐801.18802443
23 Starr TK , Jameson SC , Hogquist KA . Positive and negative selection of T cells. Annu Rev Immunol. 2003;21 :139‐176.12414722
24 Hogquist KA , Baldwin TA , Jameson SC . Central tolerance: learning self‐control in the thymus. Nat Rev Immunol. 2005;5 (10 ):772‐782.16200080
25 Klein L , Kyewski B , Allen PM , Hogquist KA . Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see). Nat Rev Immunol. 2014;14 (6 ):377‐391.24830344
26 Takada K , Kondo K , Takahama Y . Generation of peptides that promote positive selection in the thymus. J Immunol. 2017;198 (6 ):2215‐2222.28264997
27 McDonald BD , Bunker JJ , Erickson SA , Oh‐Hora M , Bendelac A . Crossreactive αβ T cell receptors are the predominant targets of thymocyte negative selection. Immunity. 2015;43 (5 ):859‐869.26522985
28 Bassing CH , Swat W , Alt FW . The mechanism and regulation of chromosomal V(D)J recombination. Cell. 2002;109 (Suppl ):S45‐S55.11983152
29 Schatz DG , Ji Y . Recombination centres and the orchestration of V(D)J recombination. Nat Rev Immunol. 2011;11 (14 ):251‐263.21394103
30 Bradley P , Thomas PG . Using T cell receptor repertoires to understand the principles of adaptive immune recognition. Annu Rev Immunol. 2019;37 :547‐570.30699000
31 Robins HS , Campregher PV , Srivastava SK , et al. Comprehensive assessment of T‐cell receptor beta‐chain diversity in alphabeta T cells. Blood. 2009;114 (19 ):4099‐4107.19706884
32 Kaplinsky J , Arnaout R . Robust estimates of overall immune‐repertoire diversity from high‐throughput measurements on samples. Nat Commun. 2016;7 :11881.27302887
33 Pannetier C , Delassus S , Darche S , Saucier C , Kourilsky P . Quantitative titration of nucleic acids by enzymatic amplification reactions run to saturation. Nucleic Acids Res. 1993;21 (3 ):577‐583.8441670
34 Fozza C , Barraqueddu F , Corda G , et al. Study of the T‐cell receptor repertoire by CDR3 spectratyping. J Immunol Methods. 2017;440 :1‐11.27823906
35 Venturi V , Price DA , Douek DC , Davenport MP . The molecular basis for public T‐cell responses? Nat Rev Immunol. 2008;8 (3 ):231‐238.18301425
36 Peruzzi B , Bencini S , Caporale R . TCR Vβ evaluation by flow cytometry. Methods Mol Biol. 2021;2285 :99‐109.33928546
37 Risitano AM , Maciejewski JP , Green S , Plasilova M , Zeng W , Young NS . In‐vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T‐cell clones by TCR beta‐CDR3 sequencing. Lancet. 2004;364 (9431 ):355‐364.15276395
38 Shugay M , Britanova OV , Merzlyak EM , et al. Towards error‐free profiling of immune repertoires. Nat Methods. 2014;11 (6 ):653‐655.24793455
39 Wu D , Sherwood A , Fromm JR , et al. High‐throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med. 2012;4 (134 ):134ra63.
40 Han A , Glanville J , Hansmann L , Davis MM . Linking T‐cell receptor sequence to functional phenotype at the single‐cell level. Nat Biotechnol. 2014;32 (7 ):684‐692.24952902
41 Robert L , Harview C , Emerson R , et al. Distinct immunological mechanisms of CTLA‐4 and PD‐1 blockade revealed by analyzing TCR usage in blood lymphocytes. Onco Targets Ther. 2014;3 :e29244.
42 Emerson RO , Sherwood AM , Rieder MJ , et al. High‐throughput sequencing of T‐cell receptors reveals a homogeneous repertoire of tumour‐infiltrating lymphocytes in ovarian cancer. J Pathol. 2013;231 (4 ):433‐440.24027095
43 Lefranc MP , Pommié C , Ruiz M , et al. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V‐like domains. Dev Comp Immunol. 2003;27 (1 ):55‐77.12477501
44 Carlson CS , Emerson RO , Sherwood AM , et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat Commun. 2013;4 :2680.24157944
45 Pai JA , Satpathy AT . High‐throughput and single‐cell T cell receptor sequencing technologies. Nat Methods. 2021;18 (8 ):881‐892.34282327
46 Ziegler CGK , Kim J , Piersanti K , et al. Constitutive activation of the B cell receptor underlies dysfunctional signaling in chronic lymphocytic leukemia. Cell Rep. 2019;28 (4 ):923‐937.e3.31340154
47 Kidman J , Principe N , Watson M , et al. Characteristics of TCR repertoire associated with successful immune checkpoint therapy responses. Front Immunol. 2020;11 :587014.33163002
48 Stewart JJ , Lee CY , Ibrahim S , et al. A Shannon entropy analysis of immunoglobulin and T cell receptor. Mol Immunol. 1997;34 (15 ):1067‐1082.9519765
49 Rempala GA , Seweryn M . Methods for diversity and overlap analysis in T‐cell receptor populations. J Math Biol. 2013;67 (6–7 ):1339‐1368.23007599
50 Sanz‐Pamplona R , Melas M , Maoz A , et al. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: a retrospective prognosis biomarker analysis. PLoS Med. 2020;17 (9 ):e1003292.32970670
51 Lan X , Cao J , Ye K , et al. TCR‐Seq identifies distinct repertoires of distant‐metastatic and nondistant‐metastatic thyroid tumors. J Clin Endocrinol Metab. 2020;105 (9 ):dgaa452.32674137
52 DeWitt WS , Emerson RO , Lindau P , et al. Dynamics of the cytotoxic T cell response to a model of acute viral infection. J Virol. 2015;89 (8 ):4517‐4526.25653453
53 Robert L , Tsoi J , Wang X , et al. CTLA4 blockade broadens the peripheral T‐cell receptor repertoire. Clin Cancer Res. 2014;20 (9 ):2424‐2432.24583799
54 Liu X , Cui Y , Zhang Y , et al. A comprehensive study of immunology repertoires in both preoperative stage and postoperative stage in patients with colorectal cancer. Mol Genet Genomic Med. 2019;7 (3 ):e504.30628178
55 Ganusov VV , De Boer RJ . Do most lymphocytes in humans really reside in the gut? Trends Immunol. 2007;28 (12 ):514‐518.17964854
56 Britanova OV , Putintseva EV , Shugay M , et al. Age‐related decrease in TCR repertoire diversity measured with deep and normalized sequence profiling. J Immunol. 2014;192 (6 ):2689‐2698.24510963
57 Warren RL , Freeman JD , Zeng T , et al. Exhaustive T‐cell repertoire sequencing of human peripheral blood samples reveals signatures of antigen selection and a directly measured repertoire size of at least 1 million clonotypes. Genome Res. 2011;21 (5 ):790‐797.21349924
58 Vanhanen R , Heikkilä N , Aggarwal K , et al. T cell receptor diversity in the human thymus. Mol Immunol. 2016;76 :116‐122.27442982
59 Wang C , Sanders CM , Yang Q , et al. High throughput sequencing reveals a complex pattern of dynamic interrelationships among human T cell subsets. Proc Natl Acad Sci USA. 2010;107 (4 ):1518‐1523.20080641
60 Kitaura K , Shini T , Matsutani T , Suzuki R . A new high‐throughput sequencing method for determining diversity and similarity of T cell receptor (TCR) α and β repertoires and identifying potential new invariant TCR α chains. BMC Immunol. 2016;17 (1 ):38.27729009
61 Fichtner AS , Ravens S , Prinz I . Human γδ TCR repertoires in health and disease. Cells. 2020;9 (4 ):800.32225004
62 Gaimann MU , Nguyen M , Desponds J , Mayer A . Early life imprints the hierarchy of T cell clone sizes. elife. 2020;9 :e61639.33345776
63 Yoshida K , Cologne JB , Cordova K , et al. Aging‐related changes in human T‐cell repertoire over 20years delineated by deep sequencing of peripheral T‐cell receptors. Exp Gerontol. 2017;96 :29‐37.28535950
64 Kallemeijn MJ , Kavelaars FG , van der Klift MY , et al. Next‐generation sequencing analysis of the human TCRγδ+ T‐cell repertoire reveals shifts in Vγ‐ and Vδ‐usage in memory populations upon aging. Front Immunol. 2018;9 :448.29559980
65 Lian J , Liu J , Yue Y , et al. The repertoire features of T cell receptor β‐chain of different age and gender groups in healthy Chinese individuals. Immunol Lett. 2019;208 :44‐51.30905825
66 Park JE , Botting RA , Conde CD , et al. A cell atlas of human thymic development defines T cell repertoire formation. Science. 2020;367 (6480 ):eaay3224.32079746
67 Palmer S , Albergante L , Blackburn CC , Newman TJ . Thymic involution and rising disease incidence with age. Proc Natl Acad Sci USA. 2018;115 (8 ):1883‐1888.29432166
68 Qi Q , Liu Y , Cheng Y , et al. Diversity and clonal selection in the human T‐cell repertoire. Proc Natl Acad Sci USA. 2014;111 (36 ):13139‐13144.25157137
69 de Greef PC , Oakes T , Gerritsen B , et al. The naive T‐cell receptor repertoire has an extremely broad distribution of clone sizes. elife. 2020;9 :e49900.32187010
70 Nikolich‐Žugich J , Slifka MK , Messaoudi I . The many important facets of T‐cell repertoire diversity. Nat Rev Immunol. 2004;4 (2 ):123‐132.15040585
71 Liu X , Hoft DF , Peng G . Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy. J Clin Invest. 2020;130 (3 ):1073‐1083.32118585
72 Mittelbrunn M , Kroemer G . Hallmarks of T cell aging. Nat Immunol. 2021;22 (6 ):687‐698.33986548
73 Zvyagin IV , Pogorelyy MV , Ivanova ME , et al. Distinctive properties of identical twins' TCR repertoires revealed by high‐throughput sequencing. Proc Natl Acad Sci USA. 2014;111 (16 ):5980‐5985.24711416
74 Greenaway HY , Ng B , Price DA , Douek DC , Davenport MP , Venturi V . NKT and MAIT invariant TCRα sequences can be produced efficiently by VJ gene recombination. Immunobiology. 2013;218 (2 ):213‐224.22647874
75 Venturi V , Rudd BD , Davenport MP . Specificity, promiscuity, and precursor frequency in immunoreceptors. Curr Opin Immunol. 2013;25 (5 ):639‐645.23880376
76 Soto C , Bombardi RG , Kozhevnikov M , et al. High frequency of shared clonotypes in human T cell receptor repertoires. Cell Rep. 2020;32 (2 ):107882.32668251
77 Heikkilä N , Vanhanen R , Yohannes DA , et al. Human thymic T cell repertoire is imprinted with strong convergence to shared sequences. Mol Immunol. 2020;127 :112‐123.32961421
78 Golding A , Darko S , Wylie WH , Douek DC , Shevach EM . Deep sequencing of the TCR‐β repertoire of human forkhead box protein 3 (FoxP3)+ and FoxP3‐ T cells suggests that they are completely distinct and non‐overlapping. Clin Exp Immunol. 2017;188 (1 ):12‐21.27880974
79 Thome JJC , Grinshpun B , Kumar BV , et al. Longterm maintenance of human naive T cells through in situ homeostasis in lymphoid tissue sites. Sci Immunol. 2016;1 (6 ):eaah6506.28361127
80 Glanville J , Kuo TC , Von Büdingen HC , et al. Naive antibody gene‐segment frequencies are heritable and unaltered by chronic lymphocyte ablation. Proc Natl Acad Sci USA. 2011;108 (50 ):20066‐20071.22123975
81 Li H , Ye C , Ji G , Han J . Determinants of public T cell responses. Cell Res. 2012;22 (1 ):33‐42.22212481
82 Jenkins MK , Moon JJ . The role of naive T cell precursor frequency and recruitment in dictating immune response magnitude. J Immunol. 2012;188 (9 ):4135‐4140.22517866
83 Parameswaran P , Liu Y , Roskin KM , et al. Convergent antibody signatures in human dengue. Cell Host Microbe. 2013;13 (6 ):691‐700.23768493
84 Scheid JF , Mouquet H , Ueberheide B , et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011;333 (6049 ):1633‐1637.21764753
85 Heikkilä N , Sormunen S , Mattila J , et al. Generation of self‐reactive, shared T‐cell receptor α chains in the human thymus. J Autoimmun. 2021;119 :102616.33652347
86 Foth S , Völkel S , Bauersachs D , Zemlin M , Skevaki C . T cell repertoire during ontogeny and characteristics in inflammatory disorders in adults and childhood. Front Immunol. 2021;11 :611573.33633732
87 Mayer‐Blackwell K , Schattgen S , Cohen‐Lavi L , et al. TCR meta‐clonotypes for biomarker discovery with tcrdist3 enabled identification of public, HLA‐restricted clusters of SARS‐CoV‐2 TCRs. elife. 2021;10 :e68605.34845983
88 Song R , Jia X , Zhao J , Du P , Zhang J . T cell receptor revision and immune repertoire changes in autoimmune diseases. Int Rev Immunol. 2022;41 (5 ):517‐533.34243694
89 Simnica D , Akyüz N , Schliffke S , et al. T cell receptor next‐generation sequencing reveals cancer‐associated repertoire metrics and reconstitution after chemotherapy in patients with hematological and solid tumors. Onco Targets Ther. 2019;8 (11 ):e1644110.
90 Liu YY , Yang QF , Yang JS , et al. Characteristics and prognostic significance of profiling the peripheral blood T‐cell receptor repertoire in patients with advanced lung cancer. Int J Cancer. 2019;145 (5 ):1423‐1431.30664810
91 Sheikh N , Cham J , Zhang L , et al. Clonotypic diversification of intratumoral T cells following sipuleucel‐T treatment in prostate cancer subjects. Cancer Res. 2016;76 (13 ):3711‐3718.27216195
92 Han Y , Liu X , Wang Y , et al. Identification of characteristic TRB V usage in HBV‐associated HCC by using differential expression profiling analysis. Onco Targets Ther. 2015;4 (8 ):e1021537.
93 Kirsch IR , Watanabe R , O'Malley JT , et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med. 2015;7 (308 ):308ra158.
94 Page DB , Yuan J , Redmond D , et al. Deep sequencing of T‐cell receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy. Cancer Immunol Res. 2016;4 (10 ):835‐844.27587469
95 Sims JS , Grinshpun B , Feng Y , et al. Diversity and divergence of the glioma‐infiltrating T‐cell receptor repertoire. Proc Natl Acad Sci USA. 2016;113 (25 ):E3529‐E3537.27261081
96 Han Y , Li H , Guan Y , Huang J . Immune repertoire: a potential biomarker and therapeutic for hepatocellular carcinoma. Cancer Lett. 2016;379 (2 ):206‐212.26188280
97 Cui JH , Lin KR , Yuan SH , et al. TCR repertoire as a novel indicator for immune monitoring and prognosis assessment of patients with cervical cancer. Front Immunol. 2018;9 :2729.30524447
98 Matsuda T , Miyauchi E , Hsu YW , et al. TCR sequencing analysis of cancer tissues and tumor draining lymph nodes in colorectal cancer patients. Onco Targets Ther. 2019;8 (6 ):e1588085.
99 Charles J , Mouret S , Challende I , et al. T‐cell receptor diversity as a prognostic biomarker in melanoma patients. Pigment Cell Melanoma Res. 2020;33 (4 ):612‐624.31971658
100 Jia Q , Zhou J , Chen G , et al. Diversity index of mucosal resident T lymphocyte repertoire predicts clinical prognosis in gastric cancer. Onco Targets Ther. 2015;4 (4 ):e1001230.
101 Wang X , Zhang B , Yang Y , et al. Characterization of distinct T cell receptor repertoires in tumor and distant non‐tumor tissues from lung cancer patients. Genomics Proteomics Bioinformatics. 2019;17 (3 ):287‐296.31479759
102 De Masson A , O'Malley JT , Elco CP , et al. High‐throughput sequencing of the T cell receptor β gene identifies aggressive early‐stage mycosis fungoides. Sci Transl Med. 2018;10 (440 ):eaar5894.29743350
103 Chung YL , Wu ML . Spatiotemporal homogeneity and distinctness of the T‐cell receptor β‐chain repertoires in Epstein‐Barr virus‐associated primary and metastatic nasopharyngeal carcinomas. Int J Cancer. 2018;143 (3 ):610‐620.29468660
104 Poschke I , Faryna M , Bergmann F , et al. Identification of a tumor‐reactive T‐cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Onco Targets Ther. 2016;5 (12 ):e1240859.
105 Chen Z , Zhang C , Pan Y , et al. T cell receptor β‐chain repertoire analysis reveals intratumour heterogeneity of tumour‐infiltrating lymphocytes in oesophageal squamous cell carcinoma. J Pathol. 2016;239 (4 ):450‐458.27171315
106 Chen Y , Xu Y , Zhao M , et al. High‐throughput T cell receptor sequencing reveals distinct repertoires between tumor and adjacent non‐tumor tissues in HBV‐associated HCC. Onco Targets Ther. 2016;5 (10 ):e1219010.
107 Sherwood AM , Emerson RO , Scherer D , et al. Tumor‐infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue. Cancer Immunol Immunother. 2013;62 (9 ):1453‐1461.23771160
108 Zhang C , Ding H , Huang H , et al. TCR repertoire intratumor heterogeneity of CD4+ and CD8+ T cells in centers and margins of localized lung adenocarcinomas. Int J Cancer. 2019;144 (4 ):818‐827.30151844
109 Gerlinger M , Quezada SA , Peggs KS , et al. Ultra‐deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. J Pathol. 2013;231 (4 ):424‐432.24122851
110 Reuben A , Spencer CN , Prieto PA , et al. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med. 2017;2 :10.28819565
111 Wang T , Wang C , Wu J , et al. The different T‐cell receptor repertoires in breast cancer tumors, draining lymph nodes, and adjacent tissues. Cancer Immunol Res. 2017;5 (2 ):148‐156.28039161
112 Reuben A , Gittelman R , Gao J , et al. TCR repertoire Intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted Neoantigen heterogeneity and postsurgical recurrence. Cancer Discov. 2017;7 (10 ):1088‐1097.28733428
113 Joshi K , Robert de Massy M , Ismail M , et al. Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nat Med. 2019;25 (10 ):1549‐1559.31591606
114 Lu Z , Zhang C , Sheng J , Shen J , Liu B . T cell receptor β‐chain repertoire analysis reveals the association between neoantigens and tumour‐infiltrating lymphocytes in multifocal papillary thyroid carcinoma. Int J Cancer. 2017;141 (2 ):377‐382.28431188
115 Abbas HA , Hao D , Tomczak K , et al. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD‐1 blockade therapy. Nat Commun. 2021;12 (1 ):6071.34663807
116 Keane C , Gould C , Jones K , et al. The T‐cell receptor repertoire influences the tumor microenvironment and is associated with survival in aggressive B‐cell lymphoma. Clin Cancer Res. 2017;23 (7 ):1820‐1828.27649554
117 Clemente MJ , Przychodzen B , Jerez A , et al. Deep sequencing of the T‐cell receptor repertoire in CD8+ T‐large granular lymphocyte leukemia identifies signature landscapes. Blood. 2013;122 (25 ):4077‐4085.24149287
118 Boyd SD , Marshall EL , Merker JD , et al. Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. Sci Transl Med. 2009;1 (12 ):12ra23.
119 Nazarov VI , Minervina AA , Komkov AY , et al. Reliability of immune receptor rearrangements as genetic markers for minimal residual disease monitoring. Bone Marrow Transplant. 2016;51 (10 ):1408‐1410.27214078
120 Feng Z , Fang Q , Kuang X , et al. Clonal expansion of bone marrow CD8+ T cells in acute myeloid leukemia patients at new diagnosis and after chemotherapy. Am J Cancer Res. 2020;10 (11 ):3973‐3989.33294280
121 Hoos A . Development of immuno‐oncology drugs ‐ from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016;15 (4 ):235‐247.26965203
122 Twyman‐Saint Victor C , Rech AJ , Maity A , et al. Radiation and dual checkpoint blockade activate non‐redundant immune mechanisms in cancer. Nature. 2015;520 (7547 ):373‐377.25754329
123 Pfirschke C , Engblom C , Rickelt S , et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity. 2016;44 (2 ):343‐354.26872698
124 Harris DT , Kranz DM . Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors. Trends Pharmacol Sci. 2016;37 (3 ):220‐230.26705086
125 Zhang J , Ji Z , Caushi JX , et al. Compartmental analysis of T‐cell clonal dynamics as a function of pathologic response to neoadjuvant PD‐1 blockade in resectable non‐small cell lung cancer. Clin Cancer Res. 2020;26 (6 ):1327‐1337.31754049
126 Chen Z , Zhang P , Xu Y , et al. Surgical stress and cancer progression: the twisted tango. Mol Cancer. 2019;18 (1 ):132.31477121
127 Manuel M , Trédan O , Bachelot T , et al. Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. Onco Targets Ther. 2012;1 (4 ):432‐440.
128 Akiyoshi T , Gotoh O , Tanaka N , et al. T‐cell complexity and density are associated with sensitivity to neoadjuvant chemoradiotherapy in patients with rectal cancer. Cancer Immunol Immunother. 2021;70 (2 ):509‐518.32845355
129 Weiner GJ . Building better monoclonal antibody‐based therapeutics. Nat Rev Cancer. 2015;15 (6 ):361‐370.25998715
130 Van Allen EM , Miao D , Schilling B , et al. Genomic correlates of response to CTLA‐4 blockade in metastatic melanoma. Science. 2015;350 (6257 ):207‐211.26359337
131 Robert C , Schachter J , Long GV , et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. 2015;372 (26 ):2521‐2532.25891173
132 Herbst RS , Baas P , Kim DW , et al. Pembrolizumab versus docetaxel for previously treated, PD‐L1‐positive, advanced non‐small‐cell lung cancer (KEYNOTE‐010): a randomised controlled trial. Lancet. 2016;387 (10027 ):1540‐1550.26712084
133 Humphries C . Adoptive cell therapy: honing that killer instinct. Nature. 2013;504 (7480 ):S13‐S15.24352359
134 Ott PA , Hu Z , Keskin DB , et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547 (7662 ):217‐221.28678778
135 Komaki Y , Komaki F , Yamada A , Micic D , Ido A , Sakuraba A . Meta‐analysis of the risk of immune‐related adverse events with anticytotoxic T‐lymphocyte‐associated antigen 4 and Antiprogrammed death 1 therapies. Clin Pharmacol Ther. 2018;103 (2 ):318‐331.28118483
136 Topalian SL , Hodi FS , Brahmer JR , et al. Safety, activity, and immune correlates of anti‐PD‐1 antibody in cancer. N Engl J Med. 2012;366 (26 ):2443‐2454.22658127
137 Cha E , Klinger M , Hou Y , et al. Improved survival with T cell clonotype stability after anti‐CTLA‐4 treatment in cancer patients. Sci Transl Med. 2014;6 (238 ):238ra70.
138 Oh DY , Cham J , Zhang L , et al. Immune toxicities Elicted by CTLA‐4 blockade in cancer patients are associated with early diversification of the T‐cell repertoire. Cancer Res. 2017;77 (6 ):1322‐1330.28031229
139 Hopkins AC , Yarchoan M , Durham JN , et al. T cell receptor repertoire features associated with survival in immunotherapy‐treated pancreatic ductal adenocarcinoma. JCI Insight. 2018;3 (13 ):e122092.29997287
140 Khunger A , Rytlewski JA , Fields P , Yusko EC , Tarhini AA . The impact of CTLA‐4 blockade and interferon‐α on clonality of T‐cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients. Onco Targets Ther. 2019;8 (11 ):e1652538.
141 Akyüz N , Brandt A , Stein A , et al. T‐cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker. Int J Cancer. 2017;140 (11 ):2535‐2544.27925177
142 Formenti SC , Rudqvist NP , Golden E , et al. Radiotherapy induces responses of lung cancer to CTLA‐4 blockade. Nat Med. 2018;24 (12 ):1845‐1851.30397353
143 Postow MA , Manuel M , Wong P , et al. Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. J Immunother Cancer. 2015;3 :23.26085931
144 Looney TJ , Topacio‐Hall D , Lowman G , et al. TCR convergence in individuals treated with immune checkpoint inhibition for cancer. Front Immunol. 2020;10 :2985.31993050
145 Tumeh PC , Harview CL , Yearley JH , et al. PD‐1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515 (7528 ):568‐571.25428505
146 Roh W , Chen PL , Reuben A , et al. Integrated molecular analysis of tumor biopsies on sequential CTLA‐4 and PD‐1 blockade reveals markers of response and resistance. Sci Transl Med. 2017;9 (379 ):eaah3560.28251903
147 Amaria RN , Reddy SM , Tawbi HA , et al. Neoadjuvant immune checkpoint blockade in high‐risk resectable melanoma. Nat Med. 2018;24 (11 ):1649‐1654.30297909
148 Yost KE , Satpathy AT , Wells DK , et al. Clonal replacement of tumor‐specific T cells following PD‐1 blockade. Nat Med. 2019;25 (8 ):1251‐1259.31359002
149 Forde PM , Chaft JE , Smith KN , et al. Neoadjuvant PD‐1 blockade in resectable lung cancer. N Engl J Med. 2018;378 (21 ):1976‐1986.29658848
150 Hogan SA , Courtier A , Cheng PF , et al. Peripheral blood TCR repertoire profiling may facilitate patient stratification for immunotherapy against melanoma. Cancer Immunol Res. 2019;7 (1 ):77‐85.30425105
151 Spassova I , Ugurel S , Terheyden P , et al. Predominance of central memory T cells with high T‐cell receptor repertoire diversity is associated with response to PD‐1/PD‐L1 inhibition in Merkel cell carcinoma. Clin Cancer Res. 2020;26 (9 ):2257‐2267.31932494
152 Han J , Duan J , Bai H , et al. TCR repertoire diversity of peripheral PD‐1+CD8+ T cells predicts clinical outcomes after immunotherapy in patients with non‐small cell lung cancer. Cancer Immunol Res. 2020;8 (1 ):146‐154.31719056
153 Saxena M , van der Burg SH , Melief CJM , Bhardwaj N . Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21 (6 ):360‐378.33907315
154 Melody SH , Shaina S , Tina W , et al. TCR sequencing can identify and track glioma‐infiltrating T cells after DC vaccination. Cancer Immunol Res. 2016;4 (5 ):412‐418.26968205
155 Carreno BM , Magrini V , Becker‐Hapak M , et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen‐specific T cells. Science. 2015;348 (6236 ):803‐808.25837513
156 Fang H , Yamaguchi R , Liu X , et al. Quantitative T cell repertoire analysis by deep cDNA sequencing of T cell receptor α and β chains using next‐generation sequencing (NGS). Onco Targets Ther. 2015;3 (12 ):e968467.
157 Vroman H , Balzaretti G , Belderbos RA , et al. T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma. J Immunother Cancer. 2020;8 (1 ):e000251.32234848
158 Maio M , Scherpereel A , Calabrò L , et al. Tremelimumab as second‐line or third‐line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double‐blind, placebo‐controlled phase 2b trial. Lancet Oncol. 2017;18 (9 ):1261‐1273.28729154
159 Quispel‐Janssen J , van der Noort V , de Vries JF , et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018;13 (10 ):1569‐1576.29908324
160 Alley EW , Lopez J , Santoro A , et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE‐028): preliminary results from a non‐randomised, open‐label, phase 1b trial. Lancet Oncol. 2017;18 (5 ):623‐630.28291584
161 Sahin U , Derhovanessian E , Miller M , et al. Personalized RNA mutanome vaccines mobilize poly‐specific therapeutic immunity against cancer. Nature. 2017;547 (7662 ):222‐226.28678784
162 Madi A , Poran A , Shifrut E , et al. T cell receptor repertoires of mice and humans are clustered in similarity networks around conserved public CDR3 sequences. elife. 2017;6 :e22057.28731407
163 Priel A , Gordin M , Philip H , Zilberberg A , Efroni S . Network representation of T‐cell repertoire‐ a novel tool to analyze immune response to cancer formation. Front Immunol. 2018;9 :2913.30619277
164 Sidhom JW , Bessell CA , Havel JJ , Kosmides A , Chan TA , Schneck JP . ImmunoMap: a bioinformatics tool for T‐cell repertoire analysis. Cancer Immunol Res. 2018;6 (2 ):151‐162.29263161
165 Mukhopadhyay M . Diving into the TCR repertoire. Nat Methods. 2021;18 (1 ):30.
